Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Amgen

Status and phase: Completed; Phase 2

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Lung Cancer; Non-Small Cell Lung Cancer; Metastatic Cancer; Hodgkin's Lymphoma; Multiple Myeloma; Non-Hodgkin's Lymphoma; Endocrine Cancer; Renal Cancer; Kidney Cancer; Thyroid Cancer; Lymphoma; Parathyroid Neoplasms; Head and Neck Cancer

Treatments: Drug: denosumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00896454

20070315

Details and patient eligibility

About

The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium </= 11.5 mg/dL (2.9 millimoles /L) by day 10.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) > 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory
• Last IV bisphosphonate treatment must be >/= to 7 days and </= to 30 days before the screening corrected serum calcium
• Adults (>/=18 years)
• Adequate organ function as defined by the following criteria:
• serum aspartate aminotransferase (AST) </= 5 x upper limit of normal (ULN)
• serum alanine aminotransferase (ALT) </= 5 x upper limit of normal
• serum total bilirubin </= 2 x upper limit of normal

Exclusion criteria

• Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease
• Receiving dialysis for renal failure
• Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC
• Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC
• Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study
• Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products)
• Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment
• Female subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment
• Subject will not be available for follow-up assessment.
• Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

33 participants in 1 patient group

denosumab

Experimental group

Description:

Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.

Treatment:

Drug: denosumab